Published in Cancer Weekly, January 15th, 2002
Along with seven patents, Procter & Gamble is donating all associated intellectual property to Mayo. As the sole new owners of the technology, Mayo will benefit from all future revenues after the technology is further developed, tested and commercialized.
"We are pleased that Mayo Clinic's international reputation as a leader in the area of lower gastrointestinal (GI) disease research has been affirmed by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.